Takotsubo cardiomyopathy with transient left ventricular obstruction successfully treated with cibenzoline succinate: A case report  by Tomofuji, Katsuhiro et al.
Journal of Cardiology Cases 11 (2015) 155–157Case Report
Takotsubo cardiomyopathy with transient left ventricular obstruction
successfully treated with cibenzoline succinate: A case report
Katsuhiro Tomofuji (MD), Shuntaro Ikeda (MD, PhD)*, Chika Murakami (MD),
Yusuke Ochiumi (MD), Masayuki Nakamura (MD), Hisaki Kadota (MD),
Hideaki Shimizu (MD), Kiyotaka Oshima (MD, PhD), Mareomi Hamada (MD, PhD, FJCC)
Department of Cardiology, Uwajima City Hospital, Uwajima, Ehime, Japan
A R T I C L E I N F O
Article history:
Received 26 November 2014
Received in revised form 27 January 2015
Accepted 30 January 2015
Keywords:
Takotsubo cardiomyopathy
Left ventricular pressure gradient
Cibenzoline
A B S T R A C T
An 84-year-old woman was urgently referred to our hospital owing to persistent malaise and chest pain.
Takotsubo cardiomyopathy was diagnosed following transthoracic echocardiography, emergency
coronary angiography, and left ventriculography. A left ventricular pressure tracing during cardiac
catheterization revealed a 72 mmHg-intraventricular pressure gradient (LVPG). Although b-blockers are
effective at reducing LVPG in takotsubo cardiomyopathy, such treatment was contraindicated in our
patient owing to her history of bronchial asthma. Therefore, we administered intravenous cibenzoline
succinate to attenuate her LVPG. The LVPG decreased to 18 mmHg within 10 min after intravenous
cibenzoline succinate administration. During her subsequent hospitalization, the patient showed
excellent functional recovery, without any complications. Left ventriculography, performed 21 days
after admission, showed normal wall motion and a left ventricular ejection fraction of 68%.
<Learning objective: The prognosis of takotsubo cardiomyopathy is generally good, however, fatal
complications have been reported. Our case demonstrated a LVPG of 72 mmHg, and b-blockers were
contraindicated because of bronchial asthma. Intravenous cibenzoline administration resulted in
successful attenuation of the patient’s LVPG. The present case suggests that cibenzoline might be
effective for the treatment of takotsubo cardiomyopathy, especially in those contraindicated for
b-blocker therapy.>
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Takotsubo cardiomyopathy is characterized by acute onset,
reversible left ventricular apical wall motion abnormalities that
simulate acute myocardial infarctions [1]. The clinical outcome is
considered to be usually good, but severe complications such as
cardiac rupture or fatal arrhythmias have been reported [2]. In
this case, we used cibenzoline succinate, a class Ia sodium
channel blocker that can be used to effectively attenuate the
pressure gradient in patients with hypertrophic obstructive
cardiomyopathy [3].
Here, we present a patient with transient, severe left ventricular
obstruction, associated with takotsubo cardiomyopathy which
was successfully treated using cibenzoline succinate.* Corresponding author at: Department of Cardiology, Uwajima City Hospital,
1-1, Goten-machi, Uwajima, Ehime 798-8510, Japan. Tel.: +81 0898 25 1111;
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An 82-year-old woman was referred to our emergency
department because of persistent malaise and accompanying
chest pain, but without any associated somatic or psychological
stress. A physical examination revealed her blood pressure 80/
58 mmHg; body temperature 36.28; respiratory rate 25 min1;
oxygen saturation 97% on room air; and heart rate 124 bpm. A
harsh 3/6 systolic murmur was heard along the left parasternal
border, and ﬁne crackles were audible in the bilateral lower lung
ﬁelds. Her chest X-ray revealed cardiomegaly and congestion.
Electrocardiography showed ST-segment elevation in II, III, aVF,
and V1–6 (Fig. 1). Laboratory tests revealed an elevated white
blood cell count (12,100 mm3), positive heart-type fatty acid
binding protein, and normal levels of creatinine kinase. Plasma
level of brain natriuretic peptide was 852 pg/ml. Echocardiogra-
phy demonstrated left ventricular apex akinesis and hyperkinesis
of the basal area, leading to the suspicion of acute coronary
syndrome or takotsubo cardiomyopathy. Hence, emergency
coronary angiography was performed (Fig. 2), with the left and reserved.
Fig. 1. Electrocardiography on admission.
Fig. 2.
Coronary angiography (CAG) and left ventriculography (LVG) on
admission. CAG did not show any signiﬁcant stenosis and LVG
revealed ballooning of the apical segments of the left ventricle and
hyperkinesis of the basal area. LCA, left coronary artery; RCA, right
coronary artery; RAO, right anterior oblique view; LAO, left anterior
oblique view.
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ventriculography revealed basal hyper-contraction and apical
ballooning. Based on these angiographic ﬁndings, the patient was
diagnosed with takotsubo cardiomyopathy. A left ventricle to
aorta pull-back pressure tracing revealed a maximum left
intraventricular pressure gradient (LVPG) of 72 mmHg (Fig. 3).
Because of the patient’s age, diagnosis of takotsubo cardiomyop-
athy with LVPG, and her broad ST-segment elevations, she was
considered to be at high risk for cardiac rupture [4]. Although b-
blockers have been shown to be effective in reducing LVPG in
patients with takotsubo cardiomyopathy [5], b-blockers were
contraindicated for our patient owing to her history of bronchial
asthma. Thus, cibenzoline succinate was intravenously adminis-
tered to reduce the LVPG.
The patient’s LVPG was re-measured 10 min after the cautious
intravenous injection of a single dose of cibenzoline succinate
(70 mg) under electrocardiographic and hemodynamic monitor-
ing. The ﬁndings showed that the maximum 72 mmHg pressure
gradient, which had been present before the intravenous
injection, decreased to 18 mmHg (Fig. 3), and her blood pressure
increased to 112/74 mmHg. A negative T-wave that was present in
the left chest leads, before cibenzoline succinate administration,
became positive. Oral cibenzoline (200 mg/day for three days)
was instituted without other medications including calcium
antagonists or other Ia anti-arrhythmic drugs. Three days after
admission, the T-waves in the I, II, aVL, aVF, and V1–6 leads became
giant negative T-waves. One month later, the giant negative
T-waves reappeared, exhibiting biphasic changes consistent with
the electrocardiographic changes of takotsubo cardiomyopathy.
Echocardiographic wall motion abnormalities disappeared within
7 days. During hospitalization, the patient showed excellent
functional recovery, without any complications. Left ventriculo-
graphy, performed 21 days after admission, showed normal wall
motion with an ejection fraction of 68%.Discussion
Ampulla cardiomyopathy (or takotsubo cardiomyopathy) is
characterized by reversible left ventricular apical wall motion
abnormalities and accompanying chest pain and electrocar-
diographic changes that simulate acute myocardial infarction.
This condition was ﬁrst reported by Satoh et al. in 1989 as part of a
retrospective study of a large administrative database [1]. The
prognosis of takotsubo cardiomyopathy is generally good,
however, fatal complications, such as ventricular arrhythmia
and cardiac rupture have been reported, and the in-hospital
mortality of patients with stress cardiomyopathy has been
reported to be 1–4% [6]. We previously reported a takotsubo
cardiomyopathy with a LVPG of 100 mmHg that was complicated
by cardiac rupture [7].
Kumar et al. reported the clinical characteristics associated with
cardiac rupture in cases of takotsubo cardiomyopathy, after
reviewing 11 cases [4]. They reported that all patients in the
rupture group were female and were signiﬁcantly older than the
controls. They concluded that the takotsubo cardiomyopathy
patients experiencing cardiac rupture had a signiﬁcantly higher
frequency of ST-segment elevations in lead II and an absence of
T-wave inversions in lead V5, upon hospital admission, than did the
controls. In addition, the mean ejection fraction, systolic blood
Fig. 3.
Effect of cibenzoline on left ventricular pressure gradient (LVPG). The
maximum LVPG (peak LV pressure–peak Ao pressure) was attenuated
from 72 mmHg to 18 mmHg following intravenous injection of
cibenzoline. ECG, electrocardiogram; AoP, aortic pressure; LVP, left
ventricular pressure.
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rupture group than among the controls.
The present patient was an elderly woman who, upon
admission, demonstrated ST-segment elevation in leads II, III,
aVF, and V1–6. She also demonstrated a maximum LVPG of
72 mmHg. Therefore, we considered the patient to be at high risk
of cardiac rupture, suggesting the need for drug intervention to
attenuate the LVPG.
To attenuate LVPG in patients with takotsubo cardiomyopathy,
Kyuma et al. reported the effective use of intravenous injections of
propranolol [5]. In their study, they investigated 13 patients with
takotsubo cardiomyopathy; propranolol was intravenously ad-
ministered within the ﬁrst 24 h after onset. They concluded that
propranolol was effective for attenuating LVPG in these patients. In
our case, b-blockers were contraindicated owing to the patient’s
history of bronchial asthma, necessitating the use of cibenzoline, a
drug demonstrated to have an attenuating effect on LVPG in
obstructive hypertrophic cardiomyopathy [3]. To date, optimal
medical management for takotsubo cardiomyopathy with LVPG
has not been fully understood. In patients with hypertrophic
obstructive cardiomyopathy, it is well known that an effective
approach includes b-blockers, class Ia anti-arrhythmic drugs, and
Ca-antagonists, which can improve hemodynamics by causing
resolution of the obstruction. These drugs are expected to
attenuate LVPG in takotsubo cardiomyopathy by a similar
mechanism. In our case, cibenzoline administration successfully
decreased the patient’s LVPG from 72 mmHg to 18 mmHg.
Prospective controlled data to deﬁne the therapeutic efﬁcacy of
these drugs are required in patients with obstructive takotsubo
cardiomyopathy.
The intracellular action of cibenzoline that is responsible for the
LVPG attenuation remains to be elucidated. In a study conducted
by Nef et al. [8], acute phase myocardial biopsies were performed
in patients with takotsubo cardiomyopathy to facilitate geneexpression analysis of the calcium regulation proteins. They
demonstrated that dephosphorylated phospholamban and over-
expressed sarcolipin signiﬁcantly decreased SERCA2a activity and
reduced its calcium afﬁnity. These ﬁndings suggested that Ca2+
uptake into the sarcoplasmic reticulum was reduced, resulting in
an increased intracellular Ca2+ concentration. The negative
inotropic effect of the Na+ channel-blocking action and the
decrease in the intracellular concentrations of calcium due to
the Ca2+ channel-blocking effect of the intravenous injection of
cibenzoline might have caused a decrease in the contractile force at
the base of the left ventricle, thereby reducing the pressure
gradient. The present case suggests that cibenzoline might be
effective for the treatment of takotsubo cardiomyopathy, especial-
ly in patients with bronchial asthma or who are otherwise
contraindicated for b-blocker therapy.
El Mahmoud et al. [9] demonstrated that the prevalence of left
ventricular outﬂow tract obstruction in takotsubo cardiomyopathy
(mean dynamic pressure gradient, 34  16 mmHg) is relatively
common (up to 25% of cases). Despite this relatively high prevalence,
guidelines, relative to disease prognosis, have not been established for
the management of takotsubo cardiomyopathy involving LVPG.
Takotsubo cardiomyopathy with LVPG carries the potential risk of
cardiac rupture; therefore, reducing the acute phase LVPG may lead to
decreased in-hospital mortality and morbidity. Additional large-scale
studies, including those assessing the relationship between LVPG
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